莱芒生物 explains its low-dose CAR-T strategy and AI-assisted drug development

What happened

莱芒生物 business vice president 仝督读 describes how its META 10-19 CAR-T therapy reached doses as low as 1‰ of conventional levels in early clinical research. He says manual production costs are below 100,000 yuan, with automation projected to bring them below 50,000 yuan. He also describes 晶泰科技’s AI-assisted IL-10 optimization, which delivered initial designs in two weeks, and ongoing AI analysis of clinical samples to investigate relapse.

Read next